Evidence map›Paper›PMID 28225601›Full record

ArticleBiochemistry2017

Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.

Carla Neckles, Sandra Eltschkner, Jason E Cummings, Maria Hirschbeck, Fereidoon Daryaee, Gopal R Bommineni, Zhuo Zhang, Lauren Spagnuolo, Weixuan Yu, Shabnam Davoodi and 3 more

Abstract read
In one paragraph

Article in Biochemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Structural approaches to pathway-specific antimicrobial agents.Translational research : the journal of laboratory and clinical medicine · 2020
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Carla NecklesInstitute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University , Stony Brook, New York 11794, United States.
Sandra EltschknerRudolf Virchow Center for Experimental Biomedicine, Institute for Structural Biology, University of Würzburg , D-97080 Würzburg, Germany.
Jason E CummingsRocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research and Department of Microbiology, Immunology and Pathology, Colorado State University , Fort Collins, Colorado 80523-0922, United States.
Maria HirschbeckRudolf Virchow Center for Experimental Biomedicine, Institute for Structural Biology, University of Würzburg , D-97080 Würzburg, Germany.
Fereidoon DaryaeeInstitute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University , Stony Brook, New York 11794, United States.
Gopal R BommineniInstitute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University , Stony Brook, New York 11794, United States.
Zhuo ZhangInstitute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University , Stony Brook, New York 11794, United States.
Lauren SpagnuoloInstitute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University , Stony Brook, New York 11794, United States.
Weixuan YuInstitute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University , Stony Brook, New York 11794, United States.
Shabnam DavoodiInstitute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University , Stony Brook, New York 11794, United States.
Richard A SlaydenRocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research and Department of Microbiology, Immunology and Pathology, Colorado State University , Fort Collins, Colorado 80523-0922, United States.
Caroline KiskerRudolf Virchow Center for Experimental Biomedicine, Institute for Structural Biology, University of Würzburg , D-97080 Würzburg, Germany.
Peter J TongeInstitute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University , Stony Brook, New York 11794, United States.ORCID 0000-0003-1606-3471

Funding

Chemotherapeutics Against Multi-Drug Resistant TuberculosisU01AI070383 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI TONGE, PETER J · 2006 to 2010
$3.4M
Mechanism of Slow Onset Enzyme Inhibition and Translation to Time-Dependent Drug ActivityR01GM102864 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI TONGE, PETER J · 2012 to 2021
$2.6M
Targetting InhA For Anti-TB Drug DiscoveryR01AI044639 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI TONGE, PETER J · 1999 to 2009
$1.9M
SBU Chemistry-Biology Interface Training ProgramT32GM092714 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI SAMPSON, NICOLE S, TONGE, PETER J · 2010 to 2019
$1.7M
Acquisition of an Applied Biosystems 4000 QTRAP Mass SpectrometerS10RR023680 · NCRR · STATE UNIVERSITY NEW YORK STONY BROOK · PI IDEN, CHARLES R · 2007 to 2007
$435k
Inhibition of Fatty Acid Biosynthesis in M. TuberculosisR21AI044639 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI TONGE, PETER J · 2003 to 2003
$252k
NCRR NIH HHS S10 RR023680NIAID NIH HHS R01 AI044639NIAID NIH HHS R21 AI044639NIAID NIH HHS U01 AI070383NIGMS NIH HHS R01 GM102864NIGMS NIH HHS T32 GM092714
6 · The paper itself

Abstract

There is growing awareness of the link between drug-target residence time and in vivo drug activity, and there are increasing efforts to determine the molecular factors that control the lifetime of a drug-target complex. Rational alterations in the drug-target residence time require knowledge of both the ground and transition states on the inhibition reaction coordinate, and we have determined the structure-kinetic relationship for 22 ethyl- or hexyl-substituted diphenyl ethers that are slow-binding inhibitors of bpFabI1, the enoyl-ACP reductase FabI1 from Burkholderia pseudomallei. Analysis of enzyme inhibition using a two-dimensional kinetic map demonstrates that the ethyl and hexyl diphenyl ethers fall into two distinct clusters. Modifications to the ethyl diphenyl ether B ring result in changes to both on and off rates, where residence times of up to ∼700 min (∼11 h) are achieved by either ground state stabilization (PT444) or transition state destabilization (slower on rate) (PT404). By contrast, modifications to the hexyl diphenyl ether B ring result in residence times of 300 min (∼5 h) through changes in only ground state stabilization (PT119). Structural analysis of nine enzyme:inhibitor complexes reveals that the variation in structure-kinetic relationships can be rationalized by structural rearrangements of bpFabI1 and subtle changes to the orientation of the inhibitor in the binding pocket. Finally, we demonstrate that three compounds with residence times on bpFabI1 from 118 min (∼2 h) to 670 min (∼11 h) have in vivo efficacy in an acute B. pseudomallei murine infection model using the virulent B. pseudomallei strain Bp400.

Indexed as

AnimalsAnti-Bacterial AgentsBacterial ProteinsBinding SitesBurkholderia pseudomalleiColony Count, MicrobialCrystallography, X-RayEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)Enzyme InhibitorsFemaleGene ExpressionKineticsLungMelioidosisMiceMice, Inbred BALB CAnti-Bacterial AgentsBacterial ProteinsEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)Enzyme InhibitorsPhenyl Ethers

Identifiers

PMID28225601
PMCPMC5401771

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.